Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2

H. Kunisue, J. Kurebayashi, T. Otsuki, C. K. Tang, M. Kurosumi, S. Yamamoto, K. Tanaka, Hiroyoshi Doihara, N. Shimizu, H. Sonoo

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

Anti-oestrogen is effective for the treatment of oestrogen receptor (ER)-positive breast carcinomas, but most of these tumours become resistant to anti-oestrogen. It has been suggested that anti-oestrogen therapy may induce a HER2 signalling pathway in breast cancer cells and this may cause resistance to anti-oestrogen. Thus, it is conceivable that combined therapy with anti-oestrogen and anti-HER2 antibody might be more effective. In the present study, we investigated the effect of combined treatment with a humanized anti-HER2 monoclonal antibody, rhumAbHER2 (trastuzumab), and an anti-oestrogen, ICI 182,780, on the cell growth of three human breast cancer cell lines which respectively express different levels of ER and HER2. The combined treatment enhanced the growth inhibitory effect on ML-20 cells, which express a high level of ER and a moderate level of HER2, but showed no additive effect on either KPL-4 cells, which express no ER and a moderate level of HER2, or MDA-MB-231 cells, which express no ER and a low level of HER2. It is also suggested that both the antibody and anti-oestrogen induce a G1-S blockade and apoptosis. These findings indicate that combined treatment with anti-HER2 antibody and anti-oestrogen may be useful for the treatment of patients with breast cancer expressing both ER and HER2.

Original languageEnglish
Pages (from-to)46-51
Number of pages6
JournalBritish Journal of Cancer
Volume82
Issue number1
Publication statusPublished - 2000

Fingerprint

Estrogen Receptors
Anti-Idiotypic Antibodies
Estrogens
Breast Neoplasms
Growth
Therapeutics
Monoclonal Antibodies
Apoptosis
Cell Line
Neoplasms

Keywords

  • Additive effect
  • Anti-HER2 antibody
  • Anti-oestrogen
  • Apoptosis
  • Breast cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kunisue, H., Kurebayashi, J., Otsuki, T., Tang, C. K., Kurosumi, M., Yamamoto, S., ... Sonoo, H. (2000). Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. British Journal of Cancer, 82(1), 46-51.

Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. / Kunisue, H.; Kurebayashi, J.; Otsuki, T.; Tang, C. K.; Kurosumi, M.; Yamamoto, S.; Tanaka, K.; Doihara, Hiroyoshi; Shimizu, N.; Sonoo, H.

In: British Journal of Cancer, Vol. 82, No. 1, 2000, p. 46-51.

Research output: Contribution to journalArticle

Kunisue, H, Kurebayashi, J, Otsuki, T, Tang, CK, Kurosumi, M, Yamamoto, S, Tanaka, K, Doihara, H, Shimizu, N & Sonoo, H 2000, 'Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2', British Journal of Cancer, vol. 82, no. 1, pp. 46-51.
Kunisue, H. ; Kurebayashi, J. ; Otsuki, T. ; Tang, C. K. ; Kurosumi, M. ; Yamamoto, S. ; Tanaka, K. ; Doihara, Hiroyoshi ; Shimizu, N. ; Sonoo, H. / Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. In: British Journal of Cancer. 2000 ; Vol. 82, No. 1. pp. 46-51.
@article{d69054d6d8d747cdaa25490798274b75,
title = "Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2",
abstract = "Anti-oestrogen is effective for the treatment of oestrogen receptor (ER)-positive breast carcinomas, but most of these tumours become resistant to anti-oestrogen. It has been suggested that anti-oestrogen therapy may induce a HER2 signalling pathway in breast cancer cells and this may cause resistance to anti-oestrogen. Thus, it is conceivable that combined therapy with anti-oestrogen and anti-HER2 antibody might be more effective. In the present study, we investigated the effect of combined treatment with a humanized anti-HER2 monoclonal antibody, rhumAbHER2 (trastuzumab), and an anti-oestrogen, ICI 182,780, on the cell growth of three human breast cancer cell lines which respectively express different levels of ER and HER2. The combined treatment enhanced the growth inhibitory effect on ML-20 cells, which express a high level of ER and a moderate level of HER2, but showed no additive effect on either KPL-4 cells, which express no ER and a moderate level of HER2, or MDA-MB-231 cells, which express no ER and a low level of HER2. It is also suggested that both the antibody and anti-oestrogen induce a G1-S blockade and apoptosis. These findings indicate that combined treatment with anti-HER2 antibody and anti-oestrogen may be useful for the treatment of patients with breast cancer expressing both ER and HER2.",
keywords = "Additive effect, Anti-HER2 antibody, Anti-oestrogen, Apoptosis, Breast cancer",
author = "H. Kunisue and J. Kurebayashi and T. Otsuki and Tang, {C. K.} and M. Kurosumi and S. Yamamoto and K. Tanaka and Hiroyoshi Doihara and N. Shimizu and H. Sonoo",
year = "2000",
language = "English",
volume = "82",
pages = "46--51",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2

AU - Kunisue, H.

AU - Kurebayashi, J.

AU - Otsuki, T.

AU - Tang, C. K.

AU - Kurosumi, M.

AU - Yamamoto, S.

AU - Tanaka, K.

AU - Doihara, Hiroyoshi

AU - Shimizu, N.

AU - Sonoo, H.

PY - 2000

Y1 - 2000

N2 - Anti-oestrogen is effective for the treatment of oestrogen receptor (ER)-positive breast carcinomas, but most of these tumours become resistant to anti-oestrogen. It has been suggested that anti-oestrogen therapy may induce a HER2 signalling pathway in breast cancer cells and this may cause resistance to anti-oestrogen. Thus, it is conceivable that combined therapy with anti-oestrogen and anti-HER2 antibody might be more effective. In the present study, we investigated the effect of combined treatment with a humanized anti-HER2 monoclonal antibody, rhumAbHER2 (trastuzumab), and an anti-oestrogen, ICI 182,780, on the cell growth of three human breast cancer cell lines which respectively express different levels of ER and HER2. The combined treatment enhanced the growth inhibitory effect on ML-20 cells, which express a high level of ER and a moderate level of HER2, but showed no additive effect on either KPL-4 cells, which express no ER and a moderate level of HER2, or MDA-MB-231 cells, which express no ER and a low level of HER2. It is also suggested that both the antibody and anti-oestrogen induce a G1-S blockade and apoptosis. These findings indicate that combined treatment with anti-HER2 antibody and anti-oestrogen may be useful for the treatment of patients with breast cancer expressing both ER and HER2.

AB - Anti-oestrogen is effective for the treatment of oestrogen receptor (ER)-positive breast carcinomas, but most of these tumours become resistant to anti-oestrogen. It has been suggested that anti-oestrogen therapy may induce a HER2 signalling pathway in breast cancer cells and this may cause resistance to anti-oestrogen. Thus, it is conceivable that combined therapy with anti-oestrogen and anti-HER2 antibody might be more effective. In the present study, we investigated the effect of combined treatment with a humanized anti-HER2 monoclonal antibody, rhumAbHER2 (trastuzumab), and an anti-oestrogen, ICI 182,780, on the cell growth of three human breast cancer cell lines which respectively express different levels of ER and HER2. The combined treatment enhanced the growth inhibitory effect on ML-20 cells, which express a high level of ER and a moderate level of HER2, but showed no additive effect on either KPL-4 cells, which express no ER and a moderate level of HER2, or MDA-MB-231 cells, which express no ER and a low level of HER2. It is also suggested that both the antibody and anti-oestrogen induce a G1-S blockade and apoptosis. These findings indicate that combined treatment with anti-HER2 antibody and anti-oestrogen may be useful for the treatment of patients with breast cancer expressing both ER and HER2.

KW - Additive effect

KW - Anti-HER2 antibody

KW - Anti-oestrogen

KW - Apoptosis

KW - Breast cancer

UR - http://www.scopus.com/inward/record.url?scp=0033986779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033986779&partnerID=8YFLogxK

M3 - Article

C2 - 10638965

AN - SCOPUS:0033986779

VL - 82

SP - 46

EP - 51

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -